Dare Bioscience shares jump 10.53% intraday after announcing DARE to PLAY Sildenafil Cream available by prescription in select states as first evidence-based topical for women.

Dare Bioscience surged 10.53% intraday, following its announcement that the DARE to PLAY sildenafil cream is now available by prescription in select states. The product, the first evidence-based topical cream for women, demonstrated increased genital blood flow and improved sexual arousal within 10-15 minutes in clinical trials. The company is a clinical-stage biopharmaceutical firm focused on women’s health, developing innovative therapies for contraception, fertility, sexual health, and vaginal health.